MAP2K7 and melanoma: The identification of driver mutations, such as BRAFv600E/K, along this pathway has led to the development of targeted therapy with dual BRAF and MEK inhibition, which has contributed to the remarkable improvement in overall survival of patients with BRAFV600 advanced melanoma [2] (Figure 1A).